Brokerage firm Avondale Partners Maintains its rating on PAREXEL International Corporation(NASDAQ:PRXL). In a research note issued to the investors, the brokerage major Lowers the price-target to $49.00 per share. The shares have been rated Underperform. The rating by Avondale Partners was issued on Apr 11, 2016.
In a different note, On Mar 28, 2016, SunTrust Robinson Humphrey said it Upgrades its rating on PAREXEL International Corporation. The shares have been rated ‘Buy’ by the firm. On Jan 25, 2016, Avondale Partners said it Downgrades its rating on PAREXEL International Corporation. According to the research note, Avondale Partners Lowers the price target to $49 per share from a prior target of $60. The shares have been rated ‘Market Underperform’ by the firm.
PAREXEL International Corporation (PRXL) shares turned negative on Fridays trading session with the shares closing down -0.08 points or -0.12% at a volume of 3,46,924. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $66.82. The peak price level was also seen at $66.82 while the days lowest was $65.42. Finally the shares closed at $66.55. The 52-week high of the shares is $76.17 while the 52-week low is $56. According to the latest information available, the market cap of the company is $3,573 M.
PAREXEL International Corporation(PRXL) last announced its earnings results on Jan 27, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $518.50M. Analysts had an estimated revenue of $523.21M. Earnings per share were $0.90. Analysts had estimated an EPS of $0.72.
Several Insider Transactions has been reported to the SEC. On Mar 3, 2016, Christopher J Lindop (director) sold 2,000 shares at $60.28 per share price.Also, On Dec 2, 2015, Richard L Love (director) sold 1,330 shares at $68.21 per share price.On Nov 24, 2015, Eduard E. Holdener (director) sold 2,200 shares at $67.66 per share price, according to the Form-4 filing with the securities and exchange commission.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.